Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
16 oct. 2024 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024...
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 oct. 2024 16h40 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors...
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
08 oct. 2024 23h55 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
08 oct. 2024 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
26 sept. 2024 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration...
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 sept. 2024 16h40 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics’ Board of Directors...
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
29 août 2024 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 août 2024 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors...
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent...
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
08 août 2024 08h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the launch of the ACRO/TRUTH healthcare provider (HCP) educational website and initiative,...